JP2014524445A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524445A5 JP2014524445A5 JP2014526241A JP2014526241A JP2014524445A5 JP 2014524445 A5 JP2014524445 A5 JP 2014524445A5 JP 2014526241 A JP2014526241 A JP 2014526241A JP 2014526241 A JP2014526241 A JP 2014526241A JP 2014524445 A5 JP2014524445 A5 JP 2014524445A5
- Authority
- JP
- Japan
- Prior art keywords
- muc1
- yeast
- composition
- immunotherapy
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 29
- 102100034256 Mucin-1 Human genes 0.000 claims 29
- 238000009169 immunotherapy Methods 0.000 claims 28
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 13
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 13
- 108020001507 fusion proteins Proteins 0.000 claims 7
- 102000037865 fusion proteins Human genes 0.000 claims 7
- 239000000556 agonist Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 230000001024 immunotherapeutic effect Effects 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 210000005253 yeast cell Anatomy 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161524407P | 2011-08-17 | 2011-08-17 | |
| US61/524,407 | 2011-08-17 | ||
| PCT/US2012/051299 WO2013025972A1 (en) | 2011-08-17 | 2012-08-17 | Yeast-muc1 immunotherapeutic compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017067243A Division JP6306238B2 (ja) | 2011-08-17 | 2017-03-30 | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014524445A JP2014524445A (ja) | 2014-09-22 |
| JP2014524445A5 true JP2014524445A5 (enExample) | 2015-10-01 |
| JP6122007B2 JP6122007B2 (ja) | 2017-04-26 |
Family
ID=47715495
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014526241A Active JP6122007B2 (ja) | 2011-08-17 | 2012-08-17 | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
| JP2017067243A Active JP6306238B2 (ja) | 2011-08-17 | 2017-03-30 | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
| JP2018040308A Active JP6571822B2 (ja) | 2011-08-17 | 2018-03-07 | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
| JP2019145946A Pending JP2019194261A (ja) | 2011-08-17 | 2019-08-08 | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017067243A Active JP6306238B2 (ja) | 2011-08-17 | 2017-03-30 | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
| JP2018040308A Active JP6571822B2 (ja) | 2011-08-17 | 2018-03-07 | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
| JP2019145946A Pending JP2019194261A (ja) | 2011-08-17 | 2019-08-08 | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9533031B2 (enExample) |
| EP (1) | EP2744918A4 (enExample) |
| JP (4) | JP6122007B2 (enExample) |
| KR (1) | KR102049928B1 (enExample) |
| CN (3) | CN109010809A (enExample) |
| AU (3) | AU2012296425B2 (enExample) |
| BR (1) | BR112014003477B1 (enExample) |
| CA (1) | CA2844500C (enExample) |
| IL (2) | IL230863B (enExample) |
| MX (1) | MX352892B (enExample) |
| RU (2) | RU2642300C2 (enExample) |
| SG (1) | SG10201607663YA (enExample) |
| WO (1) | WO2013025972A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2725450T3 (es) | 2007-07-02 | 2019-09-24 | Etubics Corp | Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples |
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| PE20140844A1 (es) | 2011-02-12 | 2014-07-14 | Globeimmune Inc | Terapeuticos a base de levadura para infeccion de la hepatitis b cronica |
| JP6068368B2 (ja) | 2011-03-17 | 2017-01-25 | グローブイミューン，インコーポレイテッド | 酵母−ブラキュリ免疫治療組成物 |
| EP2720716B1 (en) | 2011-06-14 | 2018-03-21 | Globeimmune, Inc. | Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection |
| CN109010809A (zh) * | 2011-08-17 | 2018-12-18 | 全球免疫股份有限公司 | 酵母-muc1免疫治疗组合物及其用途 |
| WO2013103658A1 (en) * | 2012-01-03 | 2013-07-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Native and agonist ctl epitopes of the muc1 tumor antigen |
| KR102103319B1 (ko) | 2012-06-26 | 2020-04-22 | 바이오디식스, 인크. | 면역반응 발생 요법으로 치료하기 위해 암환자들의 선택, 및 선택해제를 위한 질량-스펙트럼법 |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| MX374829B (es) | 2013-03-19 | 2025-03-06 | Globeimmune Inc | Composición a base de levadura para usarse para tratar cordoma. |
| US9782473B2 (en) | 2013-03-26 | 2017-10-10 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
| TWI654200B (zh) | 2013-08-30 | 2019-03-21 | 環球免疫公司 | 治療或預防結核病的組合物及方法 |
| AU2014340201B2 (en) * | 2013-10-23 | 2019-02-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use |
| CA2948803A1 (en) | 2014-04-11 | 2015-10-15 | Globeimmune, Inc. | Yeast-based immunotherapy and type i interferon sensitivity |
| WO2016105536A2 (en) * | 2014-12-23 | 2016-06-30 | University Of Maryland, Baltimore | Muc1 decoy peptides for treatment and prevention of bacterial infections |
| US10695417B2 (en) | 2015-01-09 | 2020-06-30 | Etubics Corporation | Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein |
| AU2016205215B2 (en) * | 2015-01-09 | 2021-03-11 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| US11512289B2 (en) | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11149087B2 (en) | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| JP6803339B2 (ja) | 2015-04-21 | 2020-12-23 | エンリヴェックス セラピューティクス リミテッド | 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用 |
| TWI748957B (zh) * | 2015-08-03 | 2021-12-11 | 美商環球免疫公司 | 經修飾之酵母-短尾畸型（Ｂｒａｃｈｙｕｒｙ）免疫治療組合物 |
| WO2017096247A1 (en) | 2015-12-04 | 2017-06-08 | Mayo Foundation For Medical Education And Research | Methods and vaccines for inducing immune responses to multiple different mhc molecules |
| US20190183870A1 (en) | 2016-01-05 | 2019-06-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Combination of histone deacetylase inhibitor and immunotherapy |
| CA2954892A1 (en) * | 2016-01-19 | 2017-07-19 | Pfizer Inc. | Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens |
| WO2017136342A1 (en) | 2016-02-02 | 2017-08-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells |
| JP6884155B2 (ja) | 2016-02-18 | 2021-06-09 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための併用免疫療法及びサイトカイン制御療法 |
| JP2019513021A (ja) | 2016-03-24 | 2019-05-23 | ナントセル，インコーポレイテッド | ネオエピトープ提示のための配列の配置および配列 |
| CA3061240C (en) | 2017-04-24 | 2024-01-16 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
| CN119818663A (zh) | 2018-05-15 | 2025-04-15 | 全球免疫公司 | 用于诱导细胞免疫应答的重组酵母裂解物 |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| WO2021212100A1 (en) * | 2020-04-17 | 2021-10-21 | The Trustees Of Columbia University In The City Of New York | Methods, compositions and uses thereof for reversing sacropenia |
| CN113185485B (zh) | 2021-05-10 | 2022-03-04 | 合肥立方制药股份有限公司 | 一种二氢槲皮素的半合成方法 |
| CN113214210B (zh) | 2021-05-10 | 2022-03-04 | 合肥立方制药股份有限公司 | 一种二氢槲皮素的制备方法 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| US5310654A (en) | 1985-07-31 | 1994-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for determining virulence of Yersinia |
| US5234830A (en) | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
| IL95019A0 (en) | 1989-08-09 | 1991-06-10 | Mycogen Corp | Process for encapsulation of biologicals |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
| US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| CA2282300C (en) | 1997-02-24 | 2011-08-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| DE19758400A1 (de) | 1997-12-30 | 1999-07-01 | Max Delbrueck Centrum | Tumorvakzine für MUC1-positive Karzinome |
| AU774076C (en) | 1998-12-09 | 2005-04-14 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| DE19906615A1 (de) * | 1999-02-17 | 2000-09-28 | Hanisch Franz Georg | Peptid-Varianten des Tumormarkers MUC1 und ihre Verwendung |
| WO2001018035A2 (en) * | 1999-09-08 | 2001-03-15 | Transgene S.A. | Muc-1 derived peptides |
| DE10006753A1 (de) | 2000-02-15 | 2001-08-16 | Zeiss Carl | Dreh-Schwenkeinrichtung für den Tastkopf eines Koordinatenmeßgerätes |
| US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| EP1272213B1 (en) | 2000-04-06 | 2006-03-08 | SEER Pharmaceuticals, LLC. | Microbial delivery system |
| AU2002225681A1 (en) | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| RU2004135541A (ru) * | 2002-06-11 | 2005-10-10 | ГлаксоСмитКлайн Байолоджикалз с.а. (BE) | Иммуногенные композиции |
| AU2003251531A1 (en) * | 2002-06-14 | 2003-12-31 | Diadexus, Inc. | Compositions and methods relating to breast specific genes and proteins |
| JP4914990B2 (ja) | 2002-12-16 | 2012-04-11 | グローブイミューン，インコーポレイテッド | 動物を癌から守るための治療用組成物 |
| US7439042B2 (en) * | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| US7696306B2 (en) | 2003-07-11 | 2010-04-13 | Board of Agents of the University of Nebraska | Compositions and methods for preventing or treating cancer |
| GB0321615D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| WO2005046622A2 (en) * | 2003-11-12 | 2005-05-26 | Therion Biologics Corporation | Custom vectors for treating and preventing pancreatic cancer |
| EP1687334B1 (en) * | 2003-11-24 | 2014-01-08 | MicroVAX, LLC | Mucin antigen vaccine |
| US8828957B2 (en) * | 2003-12-11 | 2014-09-09 | Microvax, Llc | Methods for generating immunity to antigen |
| JP2008504219A (ja) * | 2003-12-11 | 2008-02-14 | シドニー キンメル キャンサー センター | 抗原に対する免疫を生じさせる方法 |
| JP5060134B2 (ja) | 2003-12-12 | 2012-10-31 | ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ | ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ |
| WO2007008780A2 (en) * | 2005-07-11 | 2007-01-18 | Globeimmune, Inc. | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| US20070172503A1 (en) | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
| WO2007087420A2 (en) * | 2006-01-23 | 2007-08-02 | Recopharma Ab | Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof |
| CA2638815A1 (en) | 2006-02-02 | 2007-08-16 | Globeimmune, Inc. | Yeast-based vaccine for inducing an immune response |
| TW200806789A (en) | 2006-03-27 | 2008-02-01 | Globeimmune Inc | RAS mutation and compositions and methods related thereto |
| CN101687030B (zh) | 2007-02-02 | 2014-07-02 | 环球免疫公司 | 用于生产基于酵母的疫苗的方法 |
| WO2008115610A1 (en) | 2007-03-19 | 2008-09-25 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
| AU2008323853B8 (en) | 2007-11-08 | 2014-07-24 | Beth Israel Deaconess Medical Center | Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-CD3/CD28 |
| EP2331125A4 (en) | 2008-09-19 | 2013-03-27 | Globeimmune Inc | IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS |
| MX2011004082A (es) * | 2008-10-17 | 2011-10-14 | Dana Farber Cancer Inst Inc | Peptidos de dominio citoplasmico muc-1 como inhibidores del cancer. |
| WO2010065626A1 (en) * | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
| ES2660597T3 (es) * | 2009-04-17 | 2018-03-23 | Globeimmune, Inc. | Composiciones inmunoterápicas de combinación contra el cáncer y métodos |
| US8911722B2 (en) | 2009-09-14 | 2014-12-16 | The Regents Of The University Of Colorado, A Body Corporate | Modulation of yeast-based immunotherapy products and responses |
| US20130121964A1 (en) | 2010-03-14 | 2013-05-16 | Globeimmune, Inc. | Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy |
| WO2012019127A2 (en) | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| PE20140844A1 (es) | 2011-02-12 | 2014-07-14 | Globeimmune Inc | Terapeuticos a base de levadura para infeccion de la hepatitis b cronica |
| JP6068368B2 (ja) | 2011-03-17 | 2017-01-25 | グローブイミューン，インコーポレイテッド | 酵母−ブラキュリ免疫治療組成物 |
| EP2720716B1 (en) | 2011-06-14 | 2018-03-21 | Globeimmune, Inc. | Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection |
| CN109010809A (zh) | 2011-08-17 | 2018-12-18 | 全球免疫股份有限公司 | 酵母-muc1免疫治疗组合物及其用途 |
-
2012
- 2012-08-17 CN CN201810735110.0A patent/CN109010809A/zh active Pending
- 2012-08-17 CA CA2844500A patent/CA2844500C/en active Active
- 2012-08-17 MX MX2014001717A patent/MX352892B/es active IP Right Grant
- 2012-08-17 CN CN202210208007.7A patent/CN114617958B/zh active Active
- 2012-08-17 CN CN201280051154.2A patent/CN104024429B/zh active Active
- 2012-08-17 BR BR112014003477-0A patent/BR112014003477B1/pt active IP Right Grant
- 2012-08-17 RU RU2014109741A patent/RU2642300C2/ru active
- 2012-08-17 WO PCT/US2012/051299 patent/WO2013025972A1/en not_active Ceased
- 2012-08-17 RU RU2017143985A patent/RU2017143985A/ru not_active Application Discontinuation
- 2012-08-17 EP EP12824638.6A patent/EP2744918A4/en active Pending
- 2012-08-17 JP JP2014526241A patent/JP6122007B2/ja active Active
- 2012-08-17 KR KR1020147006872A patent/KR102049928B1/ko active Active
- 2012-08-17 SG SG10201607663YA patent/SG10201607663YA/en unknown
- 2012-08-17 AU AU2012296425A patent/AU2012296425B2/en active Active
-
2013
- 2013-03-14 US US13/803,757 patent/US9533031B2/en active Active
-
2014
- 2014-02-06 IL IL230863A patent/IL230863B/en active IP Right Grant
-
2016
- 2016-11-22 US US15/358,797 patent/US10188714B2/en active Active
-
2017
- 2017-03-30 JP JP2017067243A patent/JP6306238B2/ja active Active
- 2017-10-18 AU AU2017248462A patent/AU2017248462B2/en active Active
-
2018
- 2018-02-14 IL IL257533A patent/IL257533B/en active IP Right Grant
- 2018-03-07 JP JP2018040308A patent/JP6571822B2/ja active Active
- 2018-12-06 US US16/211,492 patent/US11065318B2/en active Active
-
2019
- 2019-08-08 JP JP2019145946A patent/JP2019194261A/ja active Pending
-
2020
- 2020-01-08 AU AU2020200137A patent/AU2020200137B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202308846B (en) | Cx3cr1-binding polypeptides | |
| JP2011155981A5 (enExample) | ||
| HK1216894A1 (zh) | 多價結合蛋白組合物 | |
| MX2014005546A (es) | Anticuerpos de union de albumina y fragmentos de union de los mismos. | |
| NZ616761A (en) | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same | |
| WO2015051199A3 (en) | Modified pseudomonas exotoxin a | |
| MX2014011066A (es) | Moleculas de union novedosas con actividad antitumoral. | |
| JP2016185981A5 (enExample) | ||
| JP2017122120A5 (enExample) | ||
| JP2016502512A5 (enExample) | ||
| WO2013040093A3 (en) | Glucagon-like peptide-2 compositions and methods of making and using same | |
| JP2014193892A5 (enExample) | ||
| JP2014064590A5 (enExample) | ||
| JP2012126742A5 (enExample) | ||
| MX2013002379A (es) | Moleculas de union a vegf. | |
| EP4223772A3 (en) | Optimized factor viii gene | |
| IN2014DN00202A (enExample) | ||
| JP2014525439A5 (enExample) | ||
| PH12015500771A1 (en) | Novel fc gamma receptor iib variants | |
| MX374403B (es) | Secuencia de endolisina kz144 modificada. | |
| WO2015051379A3 (en) | Dual specific binding proteins directed against immune cell receptors and tlr signaling autoantigens | |
| NZ702285A (en) | Staphylococcal coagulase antigens and methods of their use | |
| WO2014202208A8 (fr) | Polypeptide ayant la capacite de former des branchements d'unites glucosyle en alpha-1,3 sur un accepteur | |
| JP2013531967A5 (enExample) | ||
| WO2014162007A3 (en) | Thymic stromal lymphopoietin fragments and uses thereof |